RxDoctor Payments Data

Manana Petrov, MD

Internal Medicine · Brooklyn, NYNPI 1881620227

Payments from drug & device makers

$8,550in general payments, 2019–2025

Across 344 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$646
  • AbbVie$569
  • Novo Nordisk$507
  • Bayer$500
  • Amgen$430
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$8,48299%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,550 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$130,977
Medicare patients
138
Services billed
1,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin375$289,596
OzempicSemaglutide254$275,368
Diclofenac Sodium174$258,720
TrulicityDulaglutide173$198,472
EliquisApixaban211$161,362
SynjardyEmpagliflozin/Metformin Hcl214$156,233
FarxigaDapagliflozin Propanediol180$117,528
LinzessLinaclotide101$65,188
Diclofenac Potassium32$58,684
EntrestoSacubitril/Valsartan73$55,820
RybelsusSemaglutide48$55,339
JanumetSitagliptin Phos/Metformin Hcl73$50,242
TradjentaLinagliptin78$45,920
BiktarvyBictegrav/Emtricit/Tenofov Ala12$43,981
JanuviaSitagliptin Phosphate64$42,234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Tradjenta$308$491,749667 claims
Novo NordiskOzempic, Rybelsus$507$330,707302 claims
Lilly USA, LLCTrulicity, Mounjaro$383$213,642186 claims
PfizerEliquis$279$161,362211 claims
AstraZenecaFarxiga$1,819$117,528180 claims
MerckJanumet, Januvia$203$92,477137 claims
AbbVieLinzess$569$65,188101 claims
NovartisEntresto$646$55,82073 claims
GileadBiktarvy$83$43,98112 claims
Johnson & JohnsonXarelto$150$30,23344 claims
GSKBreo Ellipta, Shingrix, Arnuity Ellipta$412$22,37377 claims
Astellas Pharma US IncMyrbetriq$41$19,79645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →